

सं / No. 31026/16/2020-Policy  
भारत सरकार /Government of India  
रसायन और उर्वरक मंत्रालय /Ministry of Chemicals and Fertilizers  
औषध विभाग /Department of Pharmaceuticals

उद्योग भवन, नई दिल्ली-110 001  
Udyog Bhawan, New Delhi – 110 001  
Dated 19<sup>th</sup> February 2026

**Notice**

Subject: Invitation of applications for eligible products under the Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials (KSMs) / Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in the country


The Department of Pharmaceuticals had earlier invited applications for the eligible products, namely Meropenem and Ritonavir, under the Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of critical Key Starting Materials (KSMs) / Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India *vide* Notices of even number dated 26.11.2025 and 26.12.2025. The application window closed on 16<sup>th</sup> January 2026.

2. Subsequent to representations received from industry stakeholders expressing intent to participate under the Scheme, and with the approval of the Competent Authority, it has been decided to re-open the application window for the aforesaid eligible products.
3. Various conditions of the Scheme shall remain unchanged, such as allocation shall continue to be subject to available capacities, applicable annual incentive ceilings in respect of the products, and the limit of incentive up to the production tenure, i.e., up to FY2027–28 for chemical synthesis products.
4. Further, applicants — including their group companies or subsidiaries — who had previously applied under the Scheme for the same unsubscribed products and were granted approval, but subsequently withdrew or whose approval was cancelled in accordance with Clause 12.11 of the Scheme Guidelines (amended to Clause 12.13 *vide* corrigendum dated 12.03.2024) owing to non-performance or other reasons, shall not be eligible to apply for the same eligible product.
5. Accordingly, applications are invited for the following eligible products:

S. No.	Target Segment	Name of Eligible Product	Minimum Annual Production Capacity as per Scheme Guidelines (in MT)	Shortfall in Minimum Annual Production Capacity (in MT)	Maximum no. of applicants to be selected
1	Other Chemical Synthesis based KSMs/Drug Intermediates/APIs	Meropenem	4	16	4
2	Other Chemical Synthesis based KSMs/Drug Intermediates/APIs	Ritonavir	5	20	4

3. The eligible applicants may apply through online mode only (<https://plibulkdrugs.ifcilttd.com>) from 20.2.2026 to 12.3.2026. Detailed guidelines of the scheme and necessary corrigendum are available at <https://pharma-dept.gov.in/schemes>

4. The last date of receipt of complete application is 12.3.2026.



19/2/2026  
(सुहास भुइयां) (Suhās Bhūyān)

अवर सचिव, भारत सरकार

Under Secretary to the Government of India

दूरभाष / Tel: 23062531

Email: US-PharmaSchemes@pharma-dept.gov.in

To:

API manufacturers and eligible industries under the PLI scheme for Bulk Drugs

Copy to:

1. Director (Advisory Services), IFCI Limited, IFCI Tower, 61, Nehru Place, New Delhi – 110 019, for further action to open the application window for 21 days from 20.2.2026
2. Head of Group, Department of Pharmaceuticals Informatics Division, National Informatics Centre — with a request to upload this notice on the website of the Department of Pharmaceuticals